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Abstract
Background: RhoB is down-regulated in most lung cancer cell lines and tumor tissues when
compared with their normal counterparts. The mechanism of this loss of expression is not yet
deciphered.
Methods: Since no mutation has been reported in the RhoB sequence, we investigated the
epigenetic regulation of RhoB expression by analyzing the effect of HDAC inhibitors and
methyltransferase inhibitors, by direct sequencing after bisulfite treatment and by methylation
specific PCR.
Results: We first showed that histone deacetylase (HDAC) inhibitors induce a significant RhoB
re-expression in lung cancer cell lines whereas only a slight effect was observed with methyl
transferase inhibitors. As promoter methylation is the most common epigenetic process in lung
cancer, we performed methylation specific PCR and sequence analysis after bisulfite treatment and
demonstrated that RhoB was methylated neither in lung cancer cell lines nor in tumor tissues. We
also showed that a variable number of tandem repeats sequences in the 5' region of the RhoB gene
was involved in HDAC response.
Conclusion: We thus propose that RhoB regulation of expression occurs mainly by histone
deacetylation rather than by promoter hypermethylation and that this process can be modulated
by specific 5' sequences within the promoter.
Background
Identification and characterization of genetic and epige-
netic changes that drive lung cancer development and
progression is of high interest for a better understanding
of lung carcinogenesis. RhoB has been recently identified
as a gene widely involved in lung carcinogenesis [1-3].
The small GTP binding protein RhoB belongs to the Rho
subgroup (RhoA, B, and C) of the Rho protein family,
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which regulates diverse cellular processes including
cytoskeletal organization, gene transcription, cell cycle
progression, and cytokinesis [4,5]. Although RhoA and
RhoB share 86% amino acid sequence identity, RhoB dis-
plays several distinct properties such as subcellular locali-
zation in endosomes and pre-lysosomal compartment
[6], rapid turnover at a mRNA and protein level [7], post
translational modification by either farnesylation or gera-
nylgeranylation [8], and early upregulation by stress or
growth factors [9,10]. Lastly, while most Rho proteins
have been shown to have positive role in proliferation and
malignant transformation processes, RhoB rather appears
to act as a negative regulator [11,12].
It has been shown that ectopic expression of RhoB in
human tumor cells led to an inhibition of tumor growth
in nude mice [13] and that inactivation of RhoB in knock-
out mice increased the frequency of tumors [14]. We
recently showed that RhoB loss of expression occurred fre-
quently in lung carcinogenesis [1]. We showed in two
independent immunohistochemical studies that RhoB
protein was expressed in normal lung and decreased dra-
matically through lung cancer progression. Interestingly,
RhoB expression was lost in 96% of invasive tumors and
reduced by 86% in poorly differentiated tumors com-
pared with the non neoplastic epithelium. We also
showed that ectopic expression of RhoB in lung cancer cell
line A549 suppressed cell proliferation, anchorage-inde-
pendent growth, and xenograft tumor growth in nude
mice [1]. Loss of expression of RhoB has been reported in
other solid tumors such as Head and Neck carcinomas
[15] and brain tumors [16].
The mechanism by which RhoB expression decreases in
lung carcinoma is not yet elucidated. The first hypothesis
to be investigated is that RhoB loss of expression is due to
genetic alterations such as mutation or deletion. In a pre-
vious study, Adnane et al. did not find any RhoB gene
mutation in head and neck carcinoma [15]. Fritz et al. also
reported that RhoA, RhoB, and RhoC were not altered by
mutation in breast tumors [17]. More recently, Sato et al.
showed that loss of heterozygosity (LOH) in the RhoB
locus was found in 25 of 62 tumor samples analyzed [3]
but correlation between LOH and RhoB loss of expression
was not analyzed. The second hypothesis is that RhoB
expression is controlled by epigenetic events. Wang et al.
demonstrated that RhoB expression is repressed by his-
tone deacetylase 1 (HDAC1) in lung cancer cell lines [2].
We previously reported the presence of a Variable Number
of Tandem Repeat (VNTR) sequence in the human RhoB
5' region that is known to be linked with the penetrance
and the development of several cancers [18].
In order to address specifically the epigenetic regulation of
RhoB expression, we analyzed RhoB level of expression
and promoter activity after treatment with demethylating
agents and histone deacetylase inhibitors. Next, we per-
formed RhoB promoter sequencing after bisulfite treat-
ment and analyzed the involvement of the VNTR region in
epigenetic regulation.
Methods
Cell lines and tumor tissues
Human lung carcinoma cells, A549, H460 and H838,
mesothelioma cell lines, MS1 and H290 and breast cancer
cell lines MCF-7 and BT474 were purchased from ATCC
and were maintained in RMPI 1640 medium supple-
mented with 10% fetal calf serum (growth medium) at
37°C in a humidified incubator containing 5% CO2.
BEAS-2B, bronchial cells immortalized by SV40 T antigen
(ATCC CRL-9609), were maintained in DMEM (Dul-
becco's Medium Modified) supplemented with 5% fetal
calf serum at 37°C in a humidified incubator containing
5% CO2.
Fresh lung cancer tissues and adjacent normal lung tissues
from patients undergoing resection at UCSF surgery
department for lung cancers were collected at the time of
surgery and immediately snap-frozen in liquid nitrogen
(Institutional Review Board approval H8714-15319-
040). These tissue samples were kept at -170°C in a liquid
nitrogen freezer before use.
Treatment of cells with HDAC inhibitors and 
demethylating agents
5-Azacytidine (Sigma, St. Louis, MO) treatment was per-
formed as described previously [19]. Briefly, cells were
treated for 72 hours with either 1, 3 or 10 µM of 5-Azacy-
tidine each day. Trichostatin A (TSA) was purchased from
Sigma (St. Louis, MO). Cells were treated with 1 µM TSA
for 20 hours before analysis.
2'deoxy 5' azacytidine (Sigma, St. Louis, MO) treatment
was performed as described for 5-Azacytidine with a con-
centration of 10 µM.
TSA plus 5-Azacytidine combination experiments were
done by treating cells with 5-Azacytidine from day 1 to
day 3 and TSA was added for the last 20 hours (at the same
concentration than previously described).
Reverse transcription PCR
Total RNA from lung cancer cell lines, fresh lung cancer,
and paired adjacent normal tissue were isolated using an
extraction kit (RNeasy Mini kit; Qiagen, Valencia, CA).
Reverse transcription-PCR was performed in GeneAmp
PCR system 9700 using One-step reverse transcription-
PCR kit from Life Technologies, Inc., according to the
manufacturer's protocol. Primers for reverse transcription-
PCR were obtained from Operon Technologies, Inc.BMC Cancer 2007, 7:220 http://www.biomedcentral.com/1471-2407/7/220
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(Alameda, CA). Primer sequences for the human RhoB
cDNA were 5'-TCGTAAGCCCAATTAAGGGGT-3' (for-
ward) and 5'-GCTCTCTCCCGGGTCTCTCCG-3' (reverse)
[18].
Sequencing and methylation specific PCR (MSP)
Genomic DNA of the cell lines and fresh tissue samples
was extracted using DNA STAT-60 reagent (TEL-TEST, Inc.,
Friendswood, TX), according to the manufacturer proto-
col. Bisulfite modification of genomic DNA was carried
out by using a methylation kit (EZ DNA methylation kit;
Zymo Research, Orange, CA). Bisulfite-treated genomic
DNA was amplified using two pairs of primers: 5'-ATT-
TAAGTTGGGGGTTGGGAAGGG-3' (forward) and 5'-CAA
AACAACAACTCCAACCAAAC-3' (reverse), designed to
amplify nucleotides -1230 to -428 of the RhoB promoter
region; and 5'-GAGGGGTAATTTTGAATGGGAGT-3' (for-
ward) and 5'-CATAAAAACCRAACCCRAACAACA-3' (reve
rse), to amplify nucleotides -819 to +3 (the start codon
ATG of RhoB is defined as +1).
MSP analysis was done on the same cell lines and tissues
by using specific unmethylated primers: 5'-TTATTGTTTGA
GTTTGTTGTTTGAGTTTGT6-3' (forward) and 5'-AACTAC
CACAACAAAAACAATAAAAACACA-3' (reverse) and spe-
cific methylated primers: 5'-CGTTCGAGTTTGTTGTTCGA
GTTCGC-3' (forward) and 5'-CCGCGACGAAAACGATAA
AAACGCG-3' (reverse).
The PCR products were extracted from the agarose gel
using an extraction kit (QIAquick Gel Extraction kit; Qia-
gen) and were subsequently sequenced at the DNA-
sequencing Core Facility of the University of California,
San Francisco Cancer Center.
Western-blot
Cells were washed in cold PBS and harvested in lysis
buffer (Hepes 50 mM, pH 7.5, Triton X100 1%, Glycerol
10%, NaCl 10 mM, MgCl2 5 mM, NaF 25 mM, EGTA 25
mM, protease inhibitor cocktail (Sigma), sodium ortho-
vadanate 2 mM, paranitrophenylphosphate (6.4 mg/ml).
Cellular protein was quantitated by Bradford assay (Bio-
rad), and 10 to 40 µg of the cleared lysates were separated
on a 12.5% SDS-PAGE, and electro-transferred onto PVDF
membranes (Amersham Pharmacia Biotech). PVDF mem-
branes were incubated with polyclonal antibodies against
RhoB (119, Santa Cruz Biotechnology). Detection was
performed using peroxydase-conjugated secondary anti-
bodies (Biorad) and chemiluminescence detection kit
(ECL, Amersham Pharmacia Biotechnology).
Reporter gene experiment
A549 and BEAS-2B cells were stably transfected with a fire-
fly luciferase reporter gene controlled by the RhoB pro-
moter. Cells were treated with 5-Azacytidine for 3 days or
TSA for 1 day or not treated. Cells were then harvested in
Passive Lysis Buffer (Promega) then firefly luciferase activ-
ities were analyzed using Luciferase® Reporter Assay Sys-
tem (Promega) in a plate reading luminometer
(Berthold). Proteins were extracted (Biorad) and the ratio
of luciferase activity/protein quantity was calculated.
Statistical analysis
The chi-square test was used to assess differences in
reporter gene experiments (p < 0.05 was considered signif-
icant).
Results
RhoB loss of expression in lung cancer is reversed by 
histone acetylation inhibitors
We previously demonstrated RhoB loss of expression
through lung cancer progression [1]. We reported that
RhoB was expressed in normal and preinvasive tumors
whereas its expression was weak and, most of the time,
even lost in lung cancer invasive carcinoma [1]. No muta-
tion has been found in Rho genes [15,17]. As many tumor
suppressor genes are silenced by epigenetic modification
in lung cancer [20], we hypothesized that RhoB expres-
sion might be repressed by either promoter methylation
or histone deacetylation. We thus analyzed RhoB expres-
sion after treatment with a demethylating agent (5-Azacy-
tidine) or a histone deacetylase inhibitor (Trichostatin A,
TSA). We performed experiments in immortalized bron-
chial cells (BEAS-2B) and in lung cancer cell lines (A549).
We first analyzed RhoB expression by Western-blot and
showed in A549 lung cancer cell line that treatment by 5-
Azacytidine did not significantly increase RhoB expres-
sion. At the opposite, we demonstrated that RhoB silenc-
ing in lung cancer cells was reversed by histone
deacetylating agents. TSA and combination of TSA and 5-
Azacytidine dramatically increased RhoB expression. The
same tendency was observed in BEAS-2B but with less dif-
ferential effect (Figure 1A &1B). As some authors propose
that 2'-deoxy-5-azacytidine might be a more specific
demethylating agent, we performed the same experiments
with 2'-deoxy-5-azacytidine instead of 5-Azacytidine with
the same results (data not shown). We thus demonstrated
that demethylating agents cannot reverse RhoB loss of
expression.
We next analyzed luciferase activity in BEAS-2B and A549
stably transfected by a RhoB promoter construct. We first
showed that 5-Azacytidine, TSA and combination of both
were able to induce luciferase activity under the control of
RhoB promoter by a factor of respectively 2, 10.6 and 17.9
in BEAS-2B and of 2.4, 23.8 and 41.5 in A549. There is an
important differential effect between immortalized and
lung tumor cell line. Moreover, it appeared that TSA was
more potent than 5-Azacytidine to induce activity of RhoBBMC Cancer 2007, 7:220 http://www.biomedcentral.com/1471-2407/7/220
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promoter. Lastly, we demonstrated that 5-Azacytidine and
TSA were synergistic in A549 cells (Fig 2).
Analysis of RhoB promoter hypermethylation
Epigenetic modification is a frequent mechanism of inac-
tivation of tumor suppressor genes in lung cancer includ-
ing promoter hypermethylation and histone
deacetylation [21]. To unravel the respective role of these
two main mechanisms, we analyzed the sequence of RhoB
promoter after bisulfite treatment. We performed bisulfite
treatment in various normal and tumor cell lines and in
normal and tumor lung tissues. We first confirmed by
Western Blot (not shown) and RT-PCR (Fig 3) that RhoB
expression was lost or decreased in most lung cancer cells
and in lung tumors when compared with normal cell lines
or normal tissues. We first analyzed RhoB promoter [18]
and isolated many CpG islands within its sequence. An in
silico approach indicated the existence of two CpG-rich
methylation-sensitive regions spanning from -415 to
+430 and -814 to -507. We performed Methylation Spe-
cific PCR (MSP) by using primers designed to amplify spe-
cifically methylated or unmethylated region within the
promoter region. A product of amplification was only
obtained with unmethylated specific primers suggesting
that the promoter was not methylated (Fig 3).
To check more carefully the status of each CpG in the 5'
region, we designed specific primers to amplify CpG rich
regions. Sequences analysis showed a few percentage of
methylated CpG and, interestingly, no significant differ-
ence was observed either between normal cells and tumor
cells or between normal and autologous tumor tissues
(Table 1 &2, Fig 3). This data confirms that promoter
hypermethylation is not the main mechanism of RhoB
inactivation in lung cancer.
Involvement of RhoB VNTR in epigenetic regulation
We previously characterized the 5'-flanking region of
RhoB and found that it contains a Variable Number of
Tandem Repeats (VNTR) sequence that affects transcrip-
tional activity [18]. We thus analyzed if this VNTR
sequence was involved in RhoB re-expression by HDAC
inhibitors. We used deletion mutants of the 5' region con-
taining the VNTR sequences as described in our previous
work [18] and showed that TSA treatment in A549 cells
transfected with RhoB and a wild type promoter induces
an average of 60-fold RhoB re-expression whereas, when
transfected with 5' deleted promoter, re-expression was
weak (around 3.5-fold) (Fig 4). This suggests that the
VNTR containing region is involved in RhoB re-expression
by HDAC inhibitors.
Discussion
Downregulation of RhoB has been shown in lung cancer
cell lines [2] and lung cancer tissues [1,3] leading us to
investigate the mechanisms leading to its loss of expres-
sion. As many genes are mutated in lung carcinomas (K-
Ras, EGFR for example), mutational analysis of RhoB
sequence has been performed by several teams in various
tumors [3,15,17] and were all negative. Sato et al. found
an allelic loss of RhoB in 40% of the analyzed cases. Nev-
ertheless, it is not known if deletions were correlated with
RhoB level of expression and what were the mechanisms
of loss of expression for the other 60% of patients. It
should be noticed that no deletion has been found in the
RhoB gene in 12 head and neck carcinomas analyzed in
another study [15].
Aberrant methylation of the promoter region of tumor
suppressor genes and the resultant gene silencing play an
important role in many cancers and especially in lung can-
cer initiation and progression [22]. Many suppressor
A549 and BEAS-2B cells were stably transfected with a firefly  luciferase reporter gene controlled by the RhoB promoter Figure 2
A549 and BEAS-2B cells were stably transfected with a firefly 
luciferase reporter gene controlled by the RhoB promoter. 
Cells were treated with 5 AzaC (10 µM) for 3 days, TSA (1 
µM) for 1 day, combination of both or not treated (cont.). 








Cont 5 aza TSA 5 aza + TSA
BEAS 2B
A 549
Western Blot analysis of RhoB expression in Beas-2B and  A459 cell lines Figure 1
Western Blot analysis of RhoB expression in Beas-2B and 
A459 cell lines. Cells were either not treated (NT), treated 
with 5-Azacytidine (5-AzaC) at 1, 3 or 10 µM, with Trichos-
tatin (TSA) at 1 µM or with combination of TSA (1 µM) and 
5-AzaC (3 µM). Actin was used as a control. Experiments 
were performed 4 times with similar results.
AB
NT         5-AzaC   TSA TSA+
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genes such as p16, APC, Wif-1, RASSF1A [20,23,24] are
regulated through promoter hypermethylation. We found
that the RhoB promoter was rich in CpG dimers suggest-
ing that methylation might be a possible mechanism of
regulation. Moreover, we observed that treatment of lung
cancer cells with 5-Azacytidine induced a slight increase in
RhoB expression. Nevertheless, neither MSP analysis, nor
promoter sequencing after bisulfite treatment allowed us
to find CpG aberrant methylation. The same findings
were observed in lung cancer cell lines and matched nor-
mal and tumor tissues. The slight effect observed with 5-
Azacytidine might be due to regulation of other genes
upstream of RhoB. RhoB loss of expression thus appears
to be independent of promoter hypermethylation. These
results are consistent with data showing that gene hyper-
methylation is rather an early event (as demonstrated for
p16) [25] whereas RhoB loss of expression has been
shown to occur lately in cancer progression [1,15]. Never-
theless, gene hypermethylation can also occur later
through tumorigenesis.
Another major epigenetic process involved in the control
of gene expression is histone deacetylation. Using a differ-
ential DNA microarray analysis, Wang et al. showed that
RhoB gene was upregulated in response to Trapoxin (an
HDAC inhibitor) treatment. More precisely, they demon-
strated that HDAC1 repressed RhoB promoter [2]. In their
recent study, Sato et al. also found that HDAC inhibitor
RhoB expression was analyzed in various normal and cancer cell lines by RT-PCR Figure 3
RhoB expression was analyzed in various normal and cancer cell lines by RT-PCR. Expression was also analyzed in normal (N) 
and tumor (T) tissues obtained from patient operated from lung cancer. B. MSP analysis was performed on DNA extracted 
from the same cell lines and from normal and tumor tissues. U and M designed PCR product obtained with Unmethylated or 
Methylated specific primers. C. Scheme of the 5' RhoB promoter region. The 5' region of RhoB was identified previously [18]. 
We used a CpG island searcher [29] that screens for CpG islands that meet the following criteria: CG percentage > 55%; 
observed CpG/expected CpG > 0.65; length > 500 bp. This rich-CpG islands region is underlined, and all CpG are represented 
by vertical bars. D. An example of RhoB sequence after bisulfite sequencing is shown with CpG island in square. Comparison 
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treatment induced RhoB re-expression in 3 lung cancer
cell lines [3]. Moreover, HDAC1 expression in lung cancer
tissues has been shown to be correlated with cancer pro-
gression [26]. We can speculate that changes in HDAC
activity through lung cancer progression might control
expression of various genes involved in lung carcinogene-
sis. We found that RhoB expression was lost lately in lung
carcinoma and was correlated with tumor stage [1]. This
might be due to changes in HDAC expression in lung tis-
sues. A correlation analysis between HDAC and RhoB
expression in lung cancer is currently conducted in our
laboratory. In summary, we found that RhoB gene expres-
sion is controlled by histone deacetylation rather than by
methylation and that inhibition of both mechanisms was
synergistic. These two processes are linked and synergy
between demethylation and histone deacetylase inhibi-
tion in the re-expression of genes silenced in lung cancer
has already been reported [21].
Regulation of RhoB expression in lung cancer appears to
be complex and controlled by more than one mechanism.
According to our work and to the literature, the main
mechanisms are epigenetic regulation through histone
deacetylation and genetic deletion. At the opposite, gene
mutation and promoter hypermethylation have not been
reported. Epigenetic events might coexist with genetic
alterations. For example, in lung cancer, p16 is known to
be regulated by gene deletion, missense mutation or pro-
moter methylation [23]. The exact correlation between
RhoB loss of expression and the genetic or epigenetic
events has not been precisely studied yet and the respec-
tive roles of these various mechanisms remain unclear.
We can hypothesize that regulation differs according to
tumor stage or cancer type as proposed for other genes
[20].
Another level of regulation relies upon the presence of
specific sequences within the 5' region of the RhoB pro-
moter that appear to be involved in the HDAC response.
We isolated VNTR sequences located from -1124 to -821
that influence the transcriptional activity of the promoter
[18]. Here, we show that RhoB expression induced by
HDAC inhibitors is no more observed if the 5' region con-
taining the VNTR sequences is deleted. The influence of a
polymorphic VNTR sequence in human HRas on the risk
or the penetrance of several cancers has been reported
[27,28]. Wang et al. also reported that the induction of
RhoB by HDAC inhibition was mediated by an inverted
CCAAT box located in the RhoB promoter at the -451
position [2].
Conclusion
We thus propose that RhoB regulation of expression
occurs mainly by histone deacetylation rather than by
promoter hypermethylation and that this process can be
modulated by specific 5' sequences within the promoter.
We can hypothesize that reversing RhoB loss of expression
with HDAC inhibitors might be of therapeutic interest.
The same luciferase assay is performed as in figure 2 Figure 4
The same luciferase assay is performed as in figure 2. Cells 
were treated with 1 µM TSA for 72 hours. pRhoB designs 
wild type promoter and pRhoBdel. designed VNTR truncated 














Table 1: Percentage of methylated CpG in various normal and 
tumor cell lines. Sequence analysis was performed after bisulfite 
treatment.




A460 Large cell 7.9%
H838 Adenocarcinoma 8.2%




MCF-7 Breast cancer 1.6%
BT474 Breast cancer 2%
Table 2: Percentage of methylated CpG in tumor vs. normal 
tissue. Sequence analysis was performed after bisulfite 
treatment.
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